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AbstrAct
Background Recurrent cardiovascular events after 
myocardial infarction (MI) are frequent, and gender 
differences in blood pressure treatment have been 
reported. Despite increased focus on secondary 
prevention, recent reports indicate that treatment targets 
are not achieved. There is a need for gender-specific 
analyses of post-MI blood pressure treatment target 
achievement and antihypertensive medication adherence.
Design We investigated the change in systolic and 
diastolic blood pressure and antihypertensive drug use 
after first-ever MI over two time periods in a Norwegian 
population-based study.
Methods We followed 10 089 participants (55% women) 
attending the Tromsø Study in 1994–1995 (MI-cohort I) 
and 8412 participants (55% women) attending the Tromsø 
Study 2007–2008 (MI-cohort II) for first-ever MI up to their 
participation in 2007–2008 and 2015–2016, respectively. 
We used linear regression models to investigate sex and 
age differences in change in blood pressure.
Results A total of 396 participants in MI-cohort I and 
131 participants in MI-cohort II had a first-ever MI in the 
observation periods. In MI-cohort I, 35% of the women and 
52% of the men achieved the treatment targets of blood 
pressure <140/90 mm Hg (130/80 mm Hg if diabetic), 
while the proportions for MI-cohort II were 50% and 54% 
for women and men, respectively. Antihypertensive use 
was reported in 88% of women and 87% of men in MI-
cohort I, and 76% of women and 81% of men in MI-cohort 
II.
Conclusions We found an overall low achievement of the 
treatment target. The findings call for better strategies for 
secondary prevention for both women and men.
IntRoDuCtIon
Lifestyle changes and treatment adherence 
after acute myocardial infarction (MI) are 
associated with improved prognosis and 
lower mortality1; however, secondary preven-
tion is still inadequate in many European 
countries, and the majority of MI patients 
do not achieve treatment goals.2 In Norway, 
cardiovascular diseases (CVD) are the most 
common cause of inpatient hospitalisation.3 
Long-standing decrease in MI case fatality 
over four decades,4 currently as low as 10%,5 
leads to increase in the proportion of patients 
living with coronary heart disease complica-
tions.6 One of four acute MI hospitalisations 
are recurrent events, despite that >90% of all 
Norwegian MI patients are prescribed medical 
treatment such as antihypertensive drugs at 
hospital discharge,7 in accordance with Euro-
pean guidelines. The need for more intensive 
management of MI patients has previously 
been highlighted.8–11 Secondary prevention 
guidelines are gender neutral, and post-MI 
medications such as antihypertensive drug 
use have shown similar protection against 
CVD events in men and women.12 However, 
a recently published study from the SWEDE-
HEART registry13 showed that Swedish 
women were less likely to achieve treatment 
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Key messages
What is already known about this subject?
 ► Secondary prevention guidelines for myocardial 
infarction patient care are gender neutral, but 
recent studies from European countries show that 
women were less likely to achieve treatment goals 
compared with men.
What does this study add?
 ► Gender-specific analysis of achievement of blood 
pressure treatment target and antihypertensive 
medication use after myocardial infarction in a 
Norwegian general population.
How might this impact on clinical practice?
 ► Treatment target achievement is low in both 
women and men, and better strategies for 
secondary prevention are needed.
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goals for blood pressure, and a smaller proportion were 
on beta-blocker or ACE-inhibitor treatment compared 
with Swedish men. There is a need for gender-specific 
analysis of post-MI achievement of blood pressure treat-
ment target and antihypertensive medication adherence 
in the Norwegian population.
AIM
We investigated the change in systolic and diastolic blood 
pressure levels and prevalence of antihypertensive drug 
use after MI among women and men in a Norwegian 
prospective cohort study followed in two time periods.
MetHoDs
study population
The Tromsø Study9 is an ongoing population-based 
cohort study in the municipality of Tromsø, Northern 
Norway. The study includes seven waves of data collec-
tion (Tromsø 1: 1974; Tromsø 2: 1979–1980; Tromsø 3: 
1986–1987; Tromsø 4: 1994–1995; Tromsø 5: 2001–2002; 
Tromsø 6: 2007–2008; Tromsø 7: 2015–2016) to which 
total birth cohorts and representative population samples 
were invited. Response rates were between 65% and 79%. 
A total of 45 473 women and men have participated in 
one or more waves of the study. The participants have 
given written informed consent.
The present analyses include two cohorts. This allows 
comparison with coinciding EUROASPIRE studies from 
the same time periods. The basis for the first cohort were 
all Tromsø 4 participants with no prevalent MI aged 
25–74 in 1994 (n=24 984), of whom 10 154 also attended 
Tromsø 6 and formed cohort I. The basis for the second 
cohort were all Tromsø 6 participants with no preva-
lent MI aged 32–87 years in 2007 (n=12 358), and 8604 
of these also attended Tromsø 7 and formed cohort II. 
We excluded subjects who did not consent to research 
(n=1) or did not have valid blood pressure measurements 
in Tromsø 4–6 (n=65) or Tromsø 6–7 (n=61), leaving 
10 089 participants (55% women) in cohort I with base-
line 1994–1995, and 8543 participants (55% women) in 
cohort II with baseline 2007–2008, to be followed for first-
ever MI up to the next screening in 2007–2008 or 2015–
2016, respectively. Among these, 396 participants (33% 
women) had a first-ever MI during 1994–2008 (MI-cohort 
I) and 131 participants (34% women) had a first-ever MI 
during 2007–2016 (MI-cohort II). To allow for change 
in risk factors, participants with an MI <3 months prior 
to their second screening were not included MI cohort 
I. Due to lack of validated MI endpoints after 2013, in 
MI-cohort II, participants with an MI <2 years before 
their second screening were not included in MI-cohort 
II. Among the 24 984 participants of the original Tromsø 
4 invited to the Tromsø 6, 906 experienced a first-ever 
MI before 2008 and survived for at least 30 days, that is, 
510 participants with MI from the original cohort did 
not attend the second screening. Of these, 65% were not 
invited to Tromsø 6 (due to emigration (13%), mortality 
(33%) or not in the random sample invited to Tromsø 6 
(20%)). Similarly, among the 12 358 participants of the 
original Tromsø 6, 235 experienced a first-ever MI before 
2014 and survived for at least 30 days, that is, 104 partic-
ipants with MI from the original cohort did not attend 
the second screening. Of these, 43% were not invited to 
Tromsø 7 (due to emigration (10%) or mortality (33%)). 
The non-attendees were older, had a higher systolic blood 
pressure and were more likely to be smokers than those 
who attended both waves (online supplementary table 1).
Measurements, questionnaires and event validation
Blood pressure was measured on the participant’s right 
upper arm with a properly sized cuff based on arm 
circumference. Trained personnel performed all meas-
urements. Blood pressure was measured three times with 
an oscillometric digital automatic device (in Tromsø 4: 
Dinamap Vital Signs Monitor; Critikon, Tampa, Florida, 
USA, and in Tromsø 6–7: Dinamap ProCare 300 monitor, 
GE Healthcare, Norway), measurements being separated 
by a 1 min interval after 2 min seated rest. The mean of 
the two final readings was used in the analysis. Antihy-
pertensive drug use was always assessed through ques-
tionnaires and a written list of brand names of medica-
tions used on regular basis checked by health personnel 
at the study site (in Tromsø 4 only in individuals aged 
55–74 years). Self-report of medication used regularly 
for chronic conditions is considered accurate.10 Incident 
cases of CHD were recorded from each participant’s 
study entry in 1994–1995 until 31 December 2008 and 
2007–2008 until 31 December 2013, respectively. Adju-
dication of hospitalised and out-of-hospital incident MI 
was based on all available information including medical 
records from hospitals, ambulance service, general practi-
tioners, nursing homes, autopsy reports and death certif-
icates. Validation of each event was based on modified 
WHO MONICA (Multinational MONItoring of trends 
and determinants in CArdiovascular disease/MORGAM 
(MOnica Risk, Genetics, Archiving and Monograph)) 
criteria described elsewhere,14 and included clinical 
symptoms and signs, findings in ECGs, values of cardiac 
biomarkers and autopsy reports.
statistics
Statistical analyses were performed using SAS 
V.9.4 (SAS Institute). Change in blood pressure was 
defined as the difference between the values in Tromsø 6 
and Tromsø 4, and Tromsø 7 and Tromsø 6, respectively. 
Descriptive characteristics were reported with means (SD 
or 95% CIs) for continuous variables and proportions 
for binary variables. Test for differences in blood pres-
sure between baseline (pre-MI) and second screening 
(post-MI) were assessed using pairwise t-tests. Multi-
variable linear regression models were used to test for 
equality in blood pressure change between women and 
men, age groups and different groups defined by blood 
pressure levels in Tromsø 6 or Tromsø 7, respectively, or 
by levels of time between MI and the participation date 
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Table 1 Baseline characteristics by cohorts: the Tromsø Study 1994–2016
Characteristics
Cohort I, 1994–2008 Cohort II, 2007–2016
Total cohort MI cohort Total cohort MI cohort
N 10 089 396 8543 131
Age (years) 46.8 (11.7) 56.1 (8.7) 57.4 (10.5) 64.1 (9.5)
Male (%) 45.3 (4575) 67.4 (267) 45.3 (3874) 66.4 (87)
Total cholesterol (mmol/L) 6.1 (1.3) 7.0 (1.1) 5.7 (1.1) 6.1 (1.0)
Low-density lipoprotein cholesterol (mmol/L) 3.9 (1.2) 4.8 (1.0) 3.4 (1.0) 4.0 (0.9)
High-density lipoprotein cholesterol (mmol/L) 1.5 (0.4) 1.4 (0.4) 1.5 (0.4) 1.4 (0.3)
Triglycerides (mmol/L) 1.5 (1.0) 2.0 (1.1) 1.5 (0.9) 1.7 (0.9)
Systolic blood pressure (mm Hg) 133 (18.0) 145 (20.0) 133 (21.6) 146 (23.6)
Diastolic blood pressure (mm Hg) 78.1 (11.6) 85.6 (11.4) 77.6 (10.5) 82.5 (10.6)
Body mass index (kg/m2) 25.3 (3.7) 26.7 (3.4) 26.8 (4.2) 27.8 (4.5)
Daily smoking (%) 33.6 (3388) 44.2 (175) 17.9 (1517) 31.3 (41)
Values are mean (SD) or per cent (number).
MI, myocardial infarction.
Table 2 Systolic blood pressure levels after first-ever myocardial infarction  (MI) by cohort, sex and age: the Tromsø Study 
1994–2016
Age at MI  
MI-cohort I, 1994–2008 MI-cohort II, 2007–2016
N 1994–1995 2007–2008 Change (95% CI) N 2007–2008 2015–2016 Change (95% CI)
Overall 396 145.2 (20.0) 142.5 (24.1) −2.7 (−5.0 to − 0.4) 131 146.5 (23.6) 135.2 (26.1) −11.3 (−15.5 to − 7.1)
 <65 years 217 141.2 (18.7) 137.6 (21.4) −3.6 (−6.5 to − 0.6) 54 137.9 (21.3) 128.8 (17.2) −9.1 (–14.7 to − 3.5)
 ≥65 years  179 150.0 (20.6) 148.4 (26.0) −1.6 (−5.2 to 2.1) 77 152.5 (23.4) 139.7 (30.1) −12.9 (−18.9 to − 6.8)
Women
  Crude 129 149.0 (24.4) 149.7 (28.0) 0.7 (−4.1 to 5.5) 44 149.8 (28.4) 141.1 (27.8) −8.7 (−14.8 to − 2.6)
  Age-adjusted 129 146.9 (24.4) 147.3 (28.0) 0.4 (−3.7 to 4.5) 44 146.5 (28.4) 138.6 (27.8) −7.9 (−15.5 to − 0.4)
Men
  Crude 267 143.3 (17.3) 139.0 (21.2) −4.3 (−6.8 to − 1.8) 87 144.8 (20.7) 132.2 (24.8) −12.6 (−18.2 to − 7.0)
  Age-adjusted 267 144.3 (17.3) 140.2 (21.2) −4.1 (−7.0 to − 1.3) 87 146.5 (20.7) 133.5 (24.8) −13.0 (−18.3 to − 7.7)
Values are number, mean (SD or 95% CI) mm Hg.
Cardiac risk factors and prevention
in Tromsø 6 or Tromsø 7, respectively. Linear regression 
models were also used to calculate age-adjusted means 
between different groups. Logistic regression was used to 
test age-adjusted gender differences in achievement of 
treatment targets.
Results
Mean age at first MI was 67 years in women and 63 years 
in men in MI-cohort I and 71 years in women and 65 years 
in men in MI-cohort II. Differences between the total and 
the MI-cohort for each period are presented in table 1.
In MI-cohort I, the age-adjusted mean systolic blood 
pressure was 146.9 and 144.3 mm Hg at baseline (P=0.22), 
and 147.3 and 140.2 mm Hg at the second screening 
(P=0.0048), in women and men, respectively. The age-ad-
justed mean change in systolic blood pressure was 0.4 (95% 
CI −3.7 to 4.5) mm Hg in women and −4.1 (95% CI −7.0 
to −1.3) mm Hg in men (P value for sex difference=0.083) 
(table 2). In MI-cohort II, the age-adjusted mean systolic 
blood pressure was 146.5 and 146.5 mm Hg at baseline 
(P=0.98), and 138.6 and 133.5 mm Hg at the second 
screening (P=0.29), in women and men, respectively. 
The mean decrease in systolic blood pressure was −7.9 
(95% CI −15.5 to −0.4) mm Hg in women and −13.0 (95% 
CI −18.3 to −7.7) mm Hg in men (P value for sex differ-
ence=0.28) (table 2).
In MI-cohort I, the age-adjusted mean diastolic blood 
pressure was 84.7 and 86.0 at baseline (P=0.27), and 
75.3 and 77.4 mm Hg at the second screening (P=0.071), 
in women and men, respectively. The age-adjusted mean 
decrease in diastolic blood pressure was −9.4 (95% 
CI −11.6 to −7.3) mm Hg in women and −8.6 (95% CI 
−10.1 to −7.1) mm Hg in men (P value for sex differ-
ence=0.41) (table 3). In MI-cohort II, the age-adjusted 
mean diastolic blood pressure was 78.9 and 84.3 mm Hg 
at baseline (P=0.007), and 73.4 and 73.7 mm Hg at the 
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Table 3 Diastolic blood pressure levels after first-ever myocardial infarction (MI) by cohort, sex and age: the Tromsø Study 
1994–2016
Age at MI  
MI-cohort I, 1994–2008 MI-cohort II, 2007–2016
N 1994–1995 2007–2008 Change (95% CI) N 2007–2008 2015–2016 Change (95% CI)
Overall 396 85.6 (11.4) 76.7 (11.0) −8.9 (−10.1 to − 7.6) 131 82.5 (10.6) 73.6 (12.4) −8.9 (−11.3 to − 6.6)
 <65 years  217 85.6 (11.8) 78.2 (10.8) −7.3 (−9.1 to − 5.6) 54 83.4 (13.0) 75.6 (11.0) −7.9 (−11.2 to − 4.5)
≥65 years 179 85.7 (10.9) 74.9 (11.0) −10.8 (−12.5 to − 9.0) 77 81.9 (8.60) 72.2 (13.2) −9.7 (−13.0 to − 6.4)
Women
  Crude 129 85.2 (13.0) 74.8 (11.8) −10.4 (−12.7 to − 8.1) 44 79.1 (9.1) 72.8 (10.9) −6.3 (−9.7 to − 2.9)
  Age-adjusted 129 84.7 (13.0) 75.3 (11.8) −9.4 (−11.6 to − 7.3) 44 78.9 (9.1) 73.4 (10.9) −5.5 (−9.7 to − 1.4)
Men
  Crude 267 85.8 (10.5) 77.6 (10.5) −8.1 (−9.6 to − 6.7) 87 84.2 (11.0) 74.0 (13.1) −10.3 (−13.3 to −7.2)
  Age-adjusted 267 86.0 (10.5) 77.4 (10.5) −8.6 (−10.1 to − 7.1) 87 84.3 (11.0) 73.7 (13.1) −10.6 (−13.6 to −7.7)
Values are number, mean (SD or 95% CI) mm Hg.
second screening (P=0.89), in men and women, respec-
tively. The mean decrease in diastolic blood pressure was 
−5.5 (95% CI −9.7 to −1.4) mm Hg in women and −10.6 
(95% CI −13.6 to −7.7) mm Hg in men (P value for sex 
difference=0.056) (table 3).
In MI-cohort I, the age-adjusted prevalence of antihy-
pertensive drug use was 11.8% in women and 8.3% in 
men at baseline, and 88% in women and 87% in men 
at the second screening. In MI-cohort II, the age-ad-
justed prevalence of antihypertensive drug use was 31% 
and 30% at baseline, and 76% and 81% at the second 
screening in women and men, respectively.
Table 4 shows the proportion of MI patients achieving 
the treatment target for prevention of recurrent events 
(systolic blood pressure <140 mm Hg (130 mm Hg 
if diabetic) and diastolic blood pressure <90 mm Hg 
(80 mm Hg if diabetic)). In MI-cohort I, the treatment 
target was achieved by 35% of the women compared 
with 52% of the men (age-adjusted P=0.046). In MI-co-
hort II, the treatment target was achieved by 50% of the 
women compared with 54% of the men (age-adjusted 
P=0.68). No consistency was found between blood pres-
sure change and time interval between first-ever MI and 
second screening (online supplementary table 2–5).
DIsCussIon
In this study of MI patients from a general population 
followed in two study periods, we found an overall low 
achievement of the blood pressure treatment target, as 
well as some gender disparities in mean levels of blood 
pressure and treatment achievement.
Prevalence of antihypertensive drug use and overall 
achievement of treatment targets
Guidelines for control of various CVD risk factors for 
prevention of recurrent events have changed over time 
since the first Joint European Society guidelines (JESC) 
from 1994.15 An overall treatment target for blood pres-
sure of 140/90 mm Hg was introduced in the JESC2 
publication in 1998,16 with an additional treatment target 
of 130/80 mm Hg for very high-risk individuals (including 
patients with established CVD and/or diabetes) suggested 
from JESC3 in 200317 and further. Although extensively 
discussed, these continued to be the overall treatment 
goals throughout this study period17–19 and further in the 
most recently published JESC6 from 2016.20 In the third 
EUROASPIRE study conducted in 2006–2007,21 80% 
of the MI patients used beta-blockers and 71% used 
ACE-inhibitors or angiotensin II receptor blockers, and 
44% of all MI patients reached the treatment target of 
140/90 mm Hg (or 130/80 mm Hg for patients with 
diabetes). In the fourth and most recent EUROPASPIRE 
study from 2015,2 the overall prevalence of all antihy-
pertensive drug use was 78%, and 56% of all MI patients 
reached the treatment target of 140/90 mm Hg (or 
130/80 mm Hg for patients with diabetes). On average, 
the proportion of MI patients achieving the treatment 
targets and reporting use of antihypertensive drugs was 
similar in our two study periods and the coinciding third 
and fourth EUROASPIRE studies.
Gender differences in secondary prevention
The higher incidence of MI in men compared with 
women has resulted in less awareness of prevention and 
treatment in women.22 A publication from EUROASPIRE 
III showed that women were 63% less likely to achieve 
appropriate secondary prevention than men,23 and other 
previously published studies also show that women are 
less likely to use antihypertensive drugs and to achieve 
treatment targets for blood pressure control than 
men.13 23 In our study, there was a tendency (although 
not statistically significant in all analysis) towards women 
having higher systolic blood pressure, less decrease 
in blood pressure, less reported use of antihyperten-
sives and lower achievement of the treatment targets at 
follow-up. Treatment guidelines do not differ by sex, and 
meta-analyses of the effectiveness of antihypertensive 
drug therapy do not report gender differences.12 Gender 
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Cardiac risk factors and prevention
differences in antihypertensive drug use could be the 
result of lower initiation of treatment or lower adher-
ence to treatment. Lower treatment initiation after MI 
among women compared with men has been reported in 
several studies.24 25 Gender differences in adherence to 
antihypertensive drug use after MI show various results; 
some studies report women to be less adherent to antihy-
pertensive drug use compared with men,24 26 27 others do 
not report gender differences in antihypertensive drug 
adherence.27 Overall, women tend to experience MI 
somewhat later in life than men, and elderly MI patients 
are less likely to receive secondary prevention, although 
treatment of the elderly is highly beneficial.28 This could 
suggest an age–sex interaction responsible for the lower 
use of secondary prevention in women.24 25 Lower initia-
tion of antihypertensive treatment in women compared 
with men, and higher blood pressure at hospital 
discharge, has also been found in young MI patients.25
study limitations
Only 44% and 55% of the surviving MI patients in the 
original cohorts attended Tromsø 6 and Tromsø 7, respec-
tively. Non-responders among MI patients in the original 
Tromsø 4 and Tromsø 6 cohorts had higher baseline 
systolic blood pressure than responders. We assume that 
participants that did not attended Tromsø 6 or Tromsø 
7, respectively, due to death, disease or other causes were 
more prone to have a less favourable blood pressure 
profile. Thus, our results can be biased towards more 
favourable blood pressure levels than in the average MI 
population. Further, no analyses of predictors for change 
in blood pressure or medication use were included in this 
study.
ConClusIon
In this descriptive study of change in blood pressure after 
MI over time, we found an overall low achievement of the 
long-standing treatment target, consistent with previous 
studies. A larger proportion of women reached the treat-
ment goals in the last study period compared with the 
first. However, compared with men, women had higher 
follow-up mean systolic blood pressure levels in the 
second study period. The findings call for better treat-
ment strategies for secondary prevention in both women 
and men.
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